Literature DB >> 10846147

The development of polypharmacy. A longitudinal study.

L Veehof1, R Stewart, F Haaijer-Ruskamp, B M Jong.   

Abstract

BACKGROUND: To date, only a few studies have been carried out on the development and progress of polypharmacy in relation to morbidity in general practices in The Netherlands.
OBJECTIVE: The aim of this study was to investigate the relationship between an increase in long-term drug use and the incidence and severity of some chronic diseases, particularly in the elderly.
METHODS: Data on medication and morbidity of 1544 elderly people were collected for the period 1994-1997 from three family practices in the medication and morbidity Registration Network of Groningen (RNG) in the northern part of The Netherlands. Polypharmacy is defined as the long-term simultaneous use of two or more drugs; long-term is defined as >240 days in a year. We looked for differences in incidences of some chronic diseases in those subgroups of the elderly in whom multiple long-term drug use respectively increased, stayed constant or did not exist. Polypharmacy at the end of the period was predicted using regression analysis.
RESULTS: Polypharmacy occurred in 42% of the elderly at the end of 1997, with major polypharmacy (>5 drugs) in only 4%. The average number of drugs used long-term increased from 1.3 to 1.8 in 4 years. Predictors for the increase of polypharmacy were the number of drugs at the start, age, diabetes, coronary ischaemic diseases and use of medication without a clear indication (P < 0.005). The average number of diseases also increased, especially in the elderly who showed the greatest increase in long-term drug use; however, there was no significant difference from the groups with a slow or no increase in drug use. DISCUSSION: Polypharmacy showed a slow increase over 4 years: almost 20% of the elderly developed polypharmacy, i.e. going from no drugs or one drug to two or more drugs. Polypharmacy develops mainly in elderly patients who already use several drugs, who are known to suffer from cardiovascular diseases, diabetes or stomach symptoms, those who often take drugs (especially sedatives/hypnotics) without clear indication and those who develop hypertension or atrial fibrillation over time.

Entities:  

Mesh:

Year:  2000        PMID: 10846147     DOI: 10.1093/fampra/17.3.261

Source DB:  PubMed          Journal:  Fam Pract        ISSN: 0263-2136            Impact factor:   2.267


  86 in total

1.  Causes of persistent dizziness in elderly patients in primary care.

Authors:  Otto R Maarsingh; Jacquelien Dros; François G Schellevis; Henk C van Weert; Danielle A van der Windt; Gerben ter Riet; Henriette E van der Horst
Journal:  Ann Fam Med       Date:  2010 May-Jun       Impact factor: 5.166

Review 2.  Factors influencing the implementation of quality use of medicines in residential aged care.

Authors:  Julianne Cheek; Andrew Gilbert; Alison Ballantyne; Robert Penhall
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

3.  Prescribed-drug utilization and polypharmacy in a general population in Greece: association with sociodemographic, health needs, health-services utilization, and lifestyle factors.

Authors:  E Pappa; N Kontodimopoulos; A A Papadopoulos; Y Tountas; D Niakas
Journal:  Eur J Clin Pharmacol       Date:  2010-11-11       Impact factor: 2.953

4.  Determinants of change in polypharmacy status in Switzerland: the population-based CoLaus study.

Authors:  Nazanin Abolhassani; Julien Castioni; Pedro Marques-Vidal; Peter Vollenweider; Gérard Waeber
Journal:  Eur J Clin Pharmacol       Date:  2017-06-21       Impact factor: 2.953

5.  Polypharmacy among disabled Taiwanese elderly: a longitudinal observational study.

Authors:  Ding-Cheng Derrick Chan; Yi-Ting Hao; Shwu-Chong Wu
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

6.  Effect of polypharmacy, potentially inappropriate medications and anticholinergic burden on clinical outcomes: a retrospective cohort study.

Authors:  Wan-Hsuan Lu; Yu-Wen Wen; Liang-Kung Chen; Fei-Yuan Hsiao
Journal:  CMAJ       Date:  2015-02-02       Impact factor: 8.262

7.  Characteristics of polymedicated (≥ 4) elderly: a survey in a community-dwelling population aged 60 years and over.

Authors:  N Husson; G Watfa; M-C Laurain; C Perret-Guillaume; J-Y Niemier; P Miget; A Benetos
Journal:  J Nutr Health Aging       Date:  2014-01       Impact factor: 4.075

8.  Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study.

Authors:  Alessandro Nobili; Giuseppe Licata; Francesco Salerno; Luca Pasina; Mauro Tettamanti; Carlotta Franchi; Luigi De Vittorio; Alessandra Marengoni; Salvatore Corrao; Alfonso Iorio; Maura Marcucci; Pier Mannuccio Mannucci
Journal:  Eur J Clin Pharmacol       Date:  2011-01-11       Impact factor: 2.953

9.  Geographical differences in the prevalence of chronic polypharmacy in older people: eleven years of the EPIFARM-Elderly Project.

Authors:  Carlotta Franchi; Massimo Cartabia; Paolo Risso; Daniela Mari; Mauro Tettamanti; Alberto Parabiaghi; Luca Pasina; Codjo Djignefa Djade; Ida Fortino; Angela Bortolotti; Luca Merlino; Alessandro Nobili
Journal:  Eur J Clin Pharmacol       Date:  2013-03-28       Impact factor: 2.953

10.  Dizziness reported by elderly patients in family practice: prevalence, incidence, and clinical characteristics.

Authors:  Otto R Maarsingh; Jacquelien Dros; François G Schellevis; Henk C van Weert; Patrick J Bindels; Henriette E van der Horst
Journal:  BMC Fam Pract       Date:  2010-01-11       Impact factor: 2.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.